Literature DB >> 25814485

Life after ibrutinib? A new unmet need in CLL.

Javier Pinilla-Ibarz1, Julio C Chavez1.   

Abstract

In this issue of Blood, Jain et al reported on the poor outcomes of patients with chronic lymphocytic leukemia (CLL) after the discontinuation of ibrutinib.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25814485     DOI： 10.1182/blood-2015-02-622472

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  2 in total

1.  Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.

Authors:  David E Spaner; Lindsay McCaw; Guizhei Wang; Hubert Tsui; Yonghong Shi
Journal:  Cancer Med       Date:  2019-03-07       Impact factor: 4.452

2.  Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.

Authors:  David E Spaner; Yuxuan Luo; Guizhei Wang; Jennifer Gallagher; Hubert Tsui; Yonghong Shi
Journal:  Cancer Med       Date:  2021-11-17       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.